Neoadjuvant Chemotherapy in Advanced Vulvar Cancer. Issue 2 (1st February 2010)

• Record Type: Journal Article
• Authors: Domingues, Ana Patrícia; Mota, Fernando; DurÃO, Marta; Frutuoso, Cristina; Amaral, Natália; De Oliveira, Carlos Freire
• Is Part Of: International journal of gynecological cancer. Volume 20:Issue 2(2010)
• Page Start: 294-298
• Page End: 294-298
• Publication Date: 2010-02-01
• Subjects: Neoadjuvant chemotherapy -- Advanced vulvar cancer; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1111/IGC.0b013e3181c93adc
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction: Locally advanced tumors of the vulva represent approximately one third of all vulvar cancers. Therapeutic options include chemoradiation, radiotherapy, and neoadjuvant chemotherapy (NACT). Materials and Methods: Analysis of 3 NACT schemes, bleomicine, paclitaxel, and 5-fluorouracil/cisplatin, used in patients with locally advanced vulvar tumors in a 12-year period. The following parameters were evaluated and compared between regimens: age, initial tumor size, inguinal involvement, histological type, toxicities, response to treatment, surgery performed after NACT, and overall survival. Results: Of the 25 patients included, 10 underwent an NACT regimen with bleomicine (Group A); 5, with paclitaxel (Group B); and 10, with a combination of 5-fluorouracil/cisplatin (Group C). In Group A, there was a 60% response rate. Mortality was 70%, with an overall survival rate of 70%, 40%, and 30% at 12, 24, and 60 months, respectively. The mean (SD) survival was 46.7 (15.4) months. In Group B, the response rate was 40%, with an 80% mortality rate and a survival rate of 60% and 20% at 12 and 24 months, respectively. The mean (SD) survival was 17.0 (3.8) months. In Group C, 20% of the responses were observed and the mortality was 90%, with an overall survival rate of 10% at 12 and 24 months and a mean (SD) survival of 7.6 (2.0) months. Conclusion: The best response and overall survival rates were achieved in Group A with the NACT scheme of bleomicine.